Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer

Background Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative predi...

Full description

Saved in:
Bibliographic Details
Main Authors: Yi Xiao, Xi Jin, Yi-Zhou Jiang, Zhi-Ming Shao, Yi-Fan Zhou, Gen-Hong Di
Format: Article
Language:English
Published: BMJ Publishing Group 2021-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/10/e003371.full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850269644990971904
author Yi Xiao
Xi Jin
Yi-Zhou Jiang
Zhi-Ming Shao
Yi-Fan Zhou
Gen-Hong Di
author_facet Yi Xiao
Xi Jin
Yi-Zhou Jiang
Zhi-Ming Shao
Yi-Fan Zhou
Gen-Hong Di
author_sort Yi Xiao
collection DOAJ
description Background Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative predictor of outcomes after immunotherapy. However, the importance of HLA functional status in TNBCs remains poorly understood.Methods Using the largest original multiomics datasets on TNBCs, we systematically characterized the HLA-Ⅰ status of TNBCs from the perspective of HLA-Ⅰ homogeneity and loss of heterozygosity (LOH). The prognostic significance of HLA-I status was measured. To explain the potential mechanism of prognostic value in HLA-Ⅰ status, the mutational signature, copy number alteration, neoantigen and intratumoral heterogeneity were measured. Furthermore, the correlation between HLA-Ⅰ functional status and the tumor immune microenvironment was analyzed.Results LOH and homogeneity in HLA-I accounted for 18% and 21% of TNBCs, respectively. HLA-I LOH instead of HLA-I homogeneity was an independent prognostic biomarker in TNBCs. In particular, for patients with non-immune-inflamed tumors, HLA-I LOH indicated a worse prognosis than HLA-I non-LOH. Furthermore, integrated genomic and transcriptomic analysis showed that HLA-I LOH was accompanied by upregulated scores of mutational signature 3 and homologous recombination deficiency scores, which implied the failure of DNA double-strand break repair. Moreover, HLA-I LOH had higher mutation and neoantigen loads and more subclones than HLA-I non-LOH. These results indicated that although HLA-I LOH tumors with failure of DNA double-strand break repair were prone to produce neoantigens, their limited capacity for antigen presentation finally contributed to poor immune selection pressure.Conclusion Our study illustrates the genomic landscape of HLA-I functional status and stresses the prognostic significance of HLA-I LOH in TNBCs. For “cold” tumors in TNBCs, HLA-I LOH indicated a worse prognosis than HLA-I non-LOH.
format Article
id doaj-art-ff34c59247e4496494f1f33a5a8d9afd
institution OA Journals
issn 2051-1426
language English
publishDate 2021-10-01
publisher BMJ Publishing Group
record_format Article
series Journal for ImmunoTherapy of Cancer
spelling doaj-art-ff34c59247e4496494f1f33a5a8d9afd2025-08-20T01:53:00ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262021-10-0191010.1136/jitc-2021-003371Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancerYi Xiao0Xi Jin1Yi-Zhou Jiang2Zhi-Ming Shao3Yi-Fan Zhou4Gen-Hong Di51 Department of Neurology, Sichuan University, Chengdu, Sichuan, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People`s Republic of ChinaKey Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai, ChinaDepartment of Breast Surgery, Fudan University Shanghai Cancer and Key Laboratory of Breast Cancer in Shanghai, Shanghai, ChinaKey Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, People`s Republic of ChinaprofessorBackground Triple-negative breast cancers (TNBCs), especially those non-immune-inflamed tumors, have a poor prognosis and limited therapies. Human leukocyte antigen (HLA)-I not only contributes to antitumor immune response and the phenotype of the tumor microenvironment, but also is a negative predictor of outcomes after immunotherapy. However, the importance of HLA functional status in TNBCs remains poorly understood.Methods Using the largest original multiomics datasets on TNBCs, we systematically characterized the HLA-Ⅰ status of TNBCs from the perspective of HLA-Ⅰ homogeneity and loss of heterozygosity (LOH). The prognostic significance of HLA-I status was measured. To explain the potential mechanism of prognostic value in HLA-Ⅰ status, the mutational signature, copy number alteration, neoantigen and intratumoral heterogeneity were measured. Furthermore, the correlation between HLA-Ⅰ functional status and the tumor immune microenvironment was analyzed.Results LOH and homogeneity in HLA-I accounted for 18% and 21% of TNBCs, respectively. HLA-I LOH instead of HLA-I homogeneity was an independent prognostic biomarker in TNBCs. In particular, for patients with non-immune-inflamed tumors, HLA-I LOH indicated a worse prognosis than HLA-I non-LOH. Furthermore, integrated genomic and transcriptomic analysis showed that HLA-I LOH was accompanied by upregulated scores of mutational signature 3 and homologous recombination deficiency scores, which implied the failure of DNA double-strand break repair. Moreover, HLA-I LOH had higher mutation and neoantigen loads and more subclones than HLA-I non-LOH. These results indicated that although HLA-I LOH tumors with failure of DNA double-strand break repair were prone to produce neoantigens, their limited capacity for antigen presentation finally contributed to poor immune selection pressure.Conclusion Our study illustrates the genomic landscape of HLA-I functional status and stresses the prognostic significance of HLA-I LOH in TNBCs. For “cold” tumors in TNBCs, HLA-I LOH indicated a worse prognosis than HLA-I non-LOH.https://jitc.bmj.com/content/9/10/e003371.full
spellingShingle Yi Xiao
Xi Jin
Yi-Zhou Jiang
Zhi-Ming Shao
Yi-Fan Zhou
Gen-Hong Di
Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
Journal for ImmunoTherapy of Cancer
title Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
title_full Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
title_fullStr Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
title_full_unstemmed Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
title_short Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
title_sort integrated analysis reveals prognostic value of hla i loh in triple negative breast cancer
url https://jitc.bmj.com/content/9/10/e003371.full
work_keys_str_mv AT yixiao integratedanalysisrevealsprognosticvalueofhlailohintriplenegativebreastcancer
AT xijin integratedanalysisrevealsprognosticvalueofhlailohintriplenegativebreastcancer
AT yizhoujiang integratedanalysisrevealsprognosticvalueofhlailohintriplenegativebreastcancer
AT zhimingshao integratedanalysisrevealsprognosticvalueofhlailohintriplenegativebreastcancer
AT yifanzhou integratedanalysisrevealsprognosticvalueofhlailohintriplenegativebreastcancer
AT genhongdi integratedanalysisrevealsprognosticvalueofhlailohintriplenegativebreastcancer